Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWIST analysis of the ENGOT24-OV16/NOVA trial

Objective: Results from the ENGOT-OV16/NOVA study demonstrated that women with recurrent ovarian cancer who receive niraparib, a poly(ADP-ribose) polymerase inhibitor, as maintenance therapy after platinum treatment had significantly longer PFS compared to those on placebo. In addition, quality of life (QOL) data from the trial support the finding that women on niraparib had comparable QOL to those on placebo. Here we look further into QOL and estimate the time without symptoms or toxicity (TWiST) in women receiving niraparib maintenance compared with women receiving placebo.